Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YH1 in poorly controlled type 2 diabetes
NCT02752880Phase 3Completed
- Sponsor
- Chang Gung Memorial Hospital
- Start
- Jun 2016
- Primary completion
- Feb 2018
- Modality
- Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of YH1 in type 2 diabetes mellitus (T2DM), sponsored by Chang Gung Memorial Hospital. Primary endpoint: Glycohemoglobin at 12 weeks. Started Jun 2016; status: completed.
02
Drugs
YH1
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02752880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02752880.